Bain Capital Specialty Finance , Inc. (NYSE:BCSF), a specialty finance company with a market capitalization of $1.17 billion and trading near its 52-week high of $18.35, announced the issuance of $350 ...

At this time, I would like to welcome everyone to the SelectQuote's fiscal second quarter 2025 earnings call. All lines have ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment ... MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction by identifying ...

Investment to accelerate Milacron’s growth and strengthen its position as a global leader in highly engineered plastic processing solutions. Milacron’s comprehensive suite of equipment ...

“Milacron is an iconic American manufacturing business with a 50-year legacy of driving innovation in plastics,” said Matt Evans, a partner at Bain Capital Special Situations in a statement.

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It is a new position. Largay oversees the team’s debt and financing ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emerged triumphant ... of success of drug discovery is not high, continuous additional investments are ...